Navigation Links
Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors
Date:3/1/2012

CAMBRIDGE, Mass., March 1, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has elected Thomas R. Hodgson, a current member and Lead Director of Idenix's Board and former President and Chief Operating Officer of Abbott Laboratories, to serve as Chairman of the Board. Additionally, Idenix has appointed Michael S. Wyzga to its Board of Directors and he will serve as Chairman of the Audit Committee. Mr. Wyzga is currently President and Chief Executive Officer of Radius Health, Inc., a leading company developing a new generation of drug therapies for osteoporosis and women's health. Mr. Wyzga has more than 20 years of experience in the biotechnology and high-technology industries providing leadership in the areas of corporate finance, strategic planning and business development, most recently serving as Executive Vice President, Finance and Chief Financial Officer of Genzyme Corporation.

"Tom Hodgson has served on Idenix's Board for 10 years and he has made significant contributions to Idenix's progress during that time. I look forward to his continued guidance and leadership as Chairman," said Ron Renaud, President and Chief Executive Officer of Idenix.

Renaud continued, "We are also pleased to have Mike join the Idenix Board of Directors, bringing a depth of industry experience from his notable 13-year tenure with Genzyme. His financial leadership and strategic planning background will be a valuable asset to the Board as we continue to advance our pipeline of novel HCV drug candidates."

Prior to joining Radius, Mr. Wyzga was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.

About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Teri Dahlman (617) 995-9807 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
2. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
3. Idenix Pharmaceuticals to Present at the Citi Global Healthcare Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2011 Financial Results and Pipeline Update
5. Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
6. Idenix Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
7. Idenix Pharmaceuticals Prices Public Offering of Common Stock
8. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
10. Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD)
11. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... on tissue protection, repair and regeneration, today announced ... received a positive response from the U.S. FDA ... RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 is ... beta 4 ("Tß4") as the active pharmaceutical ingredient. ...
(Date:2/27/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... Ph.D., as President and Chief Executive Officer (CEO) and member ... Craig succeeds Richard Love , interim President and CEO ... Directors.  Dr. Craig has over 20 years of experience in ... Europe . "On behalf of ...
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
Breaking Medicine News(10 mins):